Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?

Absolutely not. We know that changes in amylase and lipase levels on these drugs are very common. For example, if you look at the supplementary data across the SUSTAIN series of phase 3 trials with subcutaneous semaglutide, the average person had about a 15-30% rise in their amylase/lipase. Further,...

There is no indication to do so. The base rate for pancreatitis events in RTCs is very low (0.1-0.4%), and while there is evidence that the lipase levels may change when starting the GLP-1 RA, there is no evidence linking this change to the pancreatitis event.

This elevation may be the reason why th...